Who is the manufacturer of Cabozantinib?

The original drug Cabozantinib (Cabozantinib) is developed and produced by Exelixis, Inc., a world-renowned biopharmaceutical company. As a research and development company, Exelixis is primarily responsible for the clinical research and development, quality control and global distribution of drugs. It is also responsible for drug registration, post-marketing monitoring and safety information release. The production of original drugs strictly follows GMP standards to ensure that each batch of drugs meets international standards in terms of purity, active ingredients and bioequivalence.

In some overseas markets, on the basis of original drugs, they also authorize the production of local versions or produce generic drugs through licensing to expand drug accessibility. For example, Japan, Türkiye, and some European countries have channels for locally producing or importing original drugs to ensure that patients can obtain drugs on demand. In addition, Laos and Bangladesh have significantly reduced the cost of long-term treatment through authorized or independent production of generic versions. These generic drugs usually maintain the same active ingredients and dosage forms as the original drugs, but differ in packaging, supply chain, and registration standards. Patients need to carefully choose formal channels to ensure drug safety and effectiveness.

It is worth noting that although generic drugs are more economically advantageous, they still need to undergo approval and quality monitoring by relevant regulatory authorities. Manufacturers usually strictly control the purity, dosage stability, and bioavailability of active ingredients of drugs to ensure that the clinical efficacy is equivalent to that of the original drug. At the same time, original drug manufacturers will also help doctors and patients better understand drug use regulations, monitoring methods, and adverse reaction management through education programs and patient support programs.

Overall, the production system of cabozantinib takes into account the accessibility, efficacy guarantee and affordability of patients around the world through a model that combines original drugs with authorized generic drugs, making it an important and reliable choice in the treatment of advanced cancer.

Reference:https://en.wikipedia.org/wiki/Cabozantinib